QC·VENTURES: ATAI CLOSES $ 125MN SERIES C ROUND

QC·Ventures‘ portfolio company ATAI Life Sciences AG, the world’s leading mental health biotech company has successfully raised 125mn USD in a Series-C funding round in a last step before its IPO planned for H1 2021. The placement follows the hugely successful IPO last month on NASDAQ of Compass Group (“CMPS”), one of ATAI’s portfolio companies.

The Company expects the proceeds to provide the necessary runway to accomplish several key clinical milestones in its existing mental health programs and to expand its drug candidate pipeline and further advance ATAI’s platform technologies.

Funds will continue to expand Phase 2 data readouts for arketamine in treatment resistant depression at Perception Neuroscience and ibogaine in opioid use disorder at DemeRx, as well as the completion of Phase 1 and initiation of Phase 2 trials at four other programs.

ATAI, founded by Christian Angermayer and Florian Brand in 2018, has attracted investments in this recent round amongst other by Peter Thiel’s Thiel Capital, Catalio Capital Management, Future Ventures, Galaxy Investment Partners and Falcon Edge Capital.          QC·Ventures is an investor since the first round.

About ATAI Life Sciences

ATAI is a global leading biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing. The company’s vision is to cure mental health disorders, enabling people to live healthier and happier lives.